Counselling patients after radiofrequency ablation for Barrett’s oesophagus

Radiofrequency ablation (RFA) can remove dysplastic Barrett’s oesophagus and reduce the risk of progression to oesophageal adenocarcinoma. Patients often feel relieved when treatment is complete, yet the end of ablation does not mean the end of care. Small areas of intestinal metaplasia can recur, and the underlying reflux tendency may remain.

Good counselling gives patients a clear explanation of healing, acid suppression, biopsy results and future endoscopy. It also helps them recognise symptoms that need prompt review, while avoiding unnecessary alarm about every episode of chest discomfort or indigestion.

Explain what treatment has achieved

Describe RFA as a process that treats abnormal surface tissue so that healthier squamous lining can regrow. The aim is usually complete eradication of visible lesions and intestinal metaplasia, confirmed through follow-up endoscopy and biopsies. A normal-looking lining is encouraging, but it is not proof that surveillance can stop.

Set realistic expectations about recovery. Sore throat, chest discomfort, painful swallowing and sensitivity to hot or rough foods may occur for several days. A soft diet, adequate fluids and prescribed analgesia can help. Patients should contact their treating team urgently for severe or worsening chest pain, fever, vomiting blood, black stools or an inability to swallow fluids, because these symptoms may indicate a complication.

Make surveillance understandable

Patients should know that follow-up is planned around their original diagnosis, the highest grade of dysplasia and the findings after treatment. The endoscopist may inspect the previous Barrett’s segment and the gastro-oesophageal junction carefully, then take targeted and protocol-based biopsies. The timing of the next examination is individualised rather than determined by symptoms alone.

Explain that surveillance is a safety net, not evidence that treatment has failed. Recurrent intestinal metaplasia or dysplasia can sometimes be managed with repeat ablation or another endoscopic treatment when found early. Encourage patients to keep every appointment even when swallowing and reflux symptoms have improved, since Barrett’s recurrence may be silent.

Link reflux control with long-term protection

Acid suppression is usually continued after ablation to support healing and reduce ongoing injury. Patients should take the prescribed proton pump inhibitor at the recommended time and should not stop it because symptoms have settled. Dosing may change according to healing, reflux control and specialist advice. Education on nocturnal GERD therapy can be useful when night-time symptoms continue despite treatment.

Practical measures may include avoiding meals close to bedtime, raising the head of the bed when appropriate, reducing foods that clearly trigger symptoms and moderating alcohol. In Australia, some low-dose acid-suppressing medicines are available directly from pharmacies, but patients should still check with their gastroenterologist or pharmacist before adding, changing or duplicating treatment. Persistent night symptoms deserve review rather than repeated self-medication.

Discuss symptoms without creating fear

A simple symptom plan helps patients distinguish expected recovery from warning signs. Temporary discomfort after an ablation session is different from progressive dysphagia, food sticking, unexplained weight loss, recurrent vomiting or bleeding. New or persistent symptoms should be reported to the treating service, even if the next surveillance endoscopy is months away.

Patients may also worry that every bout of heartburn signals cancer. Explain that symptoms are common and non-specific, while biopsy findings provide the key information about dysplasia. Clear written instructions, a contact number and an explanation of pathology results can reduce anxiety and prevent delays in seeking care.

Fit follow-up into Australian care

Access can vary considerably. A patient living in Sydney or Melbourne may have several specialist endoscopy services nearby, while someone in regional Queensland, Western Australia or the Northern Territory may need to travel for treatment and surveillance. Discuss transport, time away from work and whether results can be reviewed by telehealth, while ensuring that required procedures still occur at an appropriate accredited facility.

Cost and information-sharing should be addressed early. Medicare arrangements, private health insurance, specialist gap fees and repeated anaesthetic or hospital charges can affect attendance. Patients should understand how reports will be shared with their general practitioner and how information is stored in My Health Record, with privacy handled under Australia’s health-information requirements, including the Privacy Act 1988. Confirm consent for sharing results and give the patient a copy of the surveillance plan.

A written plan should state the date and purpose of the next endoscopy, the current medication schedule, dietary advice, red-flag symptoms and the clinician to contact. It should also record the original Barrett’s findings and the result that would change the surveillance interval. This gives the general practitioner, pharmacist and specialist a consistent reference point.

The most useful counselling is specific: explain what the ablation was intended to do, why acid control continues, when biopsies will be reviewed and what symptoms require action. Before leaving the clinic, the patient should write the next endoscopy date and the treating team’s contact number in their health record.